Glimepirid Aristo

Glimepirid Aristo is an oral tablet that contains the active ingredient glimepiride, a second‑generation sulfonylurea used for managing blood glucose. It is marketed in the European Union and is available only by prescription. The medication works by stimulating insulin release from pancreatic beta cells, helping to lower elevated blood sugar levels in adults with type 2 diabetes mellitus.

Glimepirid Aristo is prescribed as part of a comprehensive diabetes management plan. It is typically used when diet, exercise, and other oral agents are insufficient to achieve glycaemic control.

- Adjunct to diet and exercise in type 2 diabetes mellitus. - May be combined with metformin or other antidiabetic agents. - Used when monotherapy with other sulfonylureas is inadequate. - Considered for patients with stable renal function. - Often selected for its once‑daily dosing convenience.

Glimepirid Aristo can cause a range of side effects, most of which are mild and transient. Serious reactions are less common but require immediate medical attention.

Common: - Hypoglycaemia (low blood sugar). - Headache. - Nausea or abdominal discomfort. - Dizziness. - Weight gain. - Skin rash or itching.

Serious: - Severe hypoglycaemia with loss of consciousness. - Allergic reactions such as swelling of the face, lips, or throat. - Hepatic dysfunction indicated by jaundice. - Hematologic abnormalities like neutropenia.

Before starting Glimepirid Aristo, certain health considerations should be reviewed to minimise risks.

- Assess renal and hepatic function; dose adjustments may be needed. - Use caution in elderly patients due to increased hypoglycaemia risk. - Avoid in patients with known sulfonylurea hypersensitivity. - Monitor blood glucose regularly, especially during dose changes. - Counsel patients on recognizing and managing hypoglycaemia. - Discuss pregnancy and lactation status; safety data are limited.

Glimepirid Aristo may interact with several drug classes, affecting its efficacy or safety profile.

Avoid: - Other sulfonylureas or insulin, which can potentiate hypoglycaemia. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that increase glimepiride levels. - MAO‑B inhibitors, which may enhance hypoglycaemic effects.

Use with caution: - Beta‑blockers, which may mask hypoglycaemia symptoms. - Thiazide diuretics, potentially raising blood glucose. - Corticosteroids, which can reduce antidiabetic effectiveness. - Alcohol, as it may potentiate hypoglycaemia.